Group 1 - The company Dongyangguang Pharmaceutical (06887.HK) announced a share buyback on January 5, spending HKD 3.898 million to repurchase 89,000 shares [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 廣東東陽光藥業股份有限公司 呈交日期： 2026年1月5日 FF305 確認 不適用 第一章節註釋： 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06887 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | ...

Core Insights - Dongyangguang Pharmaceutical (06887) has announced the development of HECN30227, a first-in-class drug with global intellectual property rights, capable of eliminating both cccDNA and intDNA derived HBsAg, showing superior efficacy compared to clinical competitors [1] - The drug utilizes the unique HEC GalNova liver-targeted delivery system, which enhances precision and reduces off-target risks, with the first domestic subject enrolled in clinical trials [1] - HECN30227's combination therapy with the immunomodulator HEC191834 has been recognized as a "Poster of Distinction" at the 2025 AASLD annual meeting, indicating high international academic recognition for its clinical development potential [1] Research and Development - Since 2022, the company has entered the small nucleic acid field, establishing a comprehensive R&D platform covering target discovery, sequence design and synthesis, chemical modification, delivery technology, and biological evaluation, positioning itself among the top tier in China [2] - The company has applied for over 50 patents and is developing more than 10 small nucleic acid pipelines across four major areas: anti-infection, cardiovascular-renal-metabolic, respiratory system, and oncology, with plans to advance multiple small nucleic acid drugs into clinical stages annually [2] Clinical Pipeline - Key preclinical products include HECN30227 and a "siRNA + ASO + immunomodulator" triple therapy for hepatitis B, which shows superior efficacy compared to competitors [3] - The dual-target series aims to silence two pathogenic genes or multiple regions of the same gene, providing effective solutions for complex diseases, with several molecules demonstrating strong and lasting activity in large animal models [3] - The company is also advancing dual-target pipelines for conditions like MASH, as well as fat-targeting, lung-targeting, and antibody delivery (AOC) pipelines, with plans to progress these to clinical stages [3] Strategic Direction - The company is leading the innovation wave in China's small nucleic acid drugs through a "technology + pipeline + industrialization" strategy, focusing on building its small nucleic acid technology platform and addressing unmet clinical needs [4]

Group 1 - The core product HECN30227 is a first-in-class drug developed by the company, targeting both cccDNA and intDNA sources of hepatitis B surface antigen (HBsAg) with global intellectual property rights [1] - Preclinical data indicates that HECN30227 exhibits pan-genotypic activity, effectively reducing HBsAg levels and maintaining efficacy against nucleoside drug-resistant strains, outperforming clinical competitors in both in vitro and in vivo efficacy [1] - HECN30227 utilizes the company's unique HEC-GalNova liver-targeted delivery system, achieving precise and efficient liver delivery while significantly reducing off-target risks [1] Group 2 - Since 2022, the company has entered the small nucleic acid field, establishing a comprehensive R&D platform covering target discovery, sequence design and synthesis, chemical modification, delivery technology, and biological evaluation, positioning itself among the top tier in China [2] - The company has applied for over 50 patents and developed more than 10 small nucleic acid pipelines across four major areas: anti-infection, cardiovascular-kidney-metabolism, respiratory system, and oncology, with plans to advance multiple small nucleic acid drugs into clinical stages annually [2] - The company is leading the innovation wave in China's small nucleic acid drugs through a multi-faceted approach of "technology + pipeline + industrialization," aiming to address unmet clinical needs and provide globally competitive "China-made" treatment solutions [2]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 SUNSHINE LAKE PHARMA CO., LTD. 廣 東 東 陽 光 藥 業 股 份 有 限 公 司 （在中華人民共和國註冊成立之股份有限公司） （股份代號：6887） 自願性公告 HECN30227（靶向乙型肝炎病毒的si RNA藥物）的 I期臨床及小核酸平台研發進展的公告 本 公 告 由 廣 東 東 陽 光 藥 業 股 份 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團」）自願刊發。 關於小核酸技術平台 本 集 團 自 2022 年 起 進 軍 小 核 酸 領 域 ， 構 建 了「 靶 點 發 現 - 序 列 設 計 與 合 成 - 化 學 修 飾 - 遞 送 技 術 - 生 物 學 評 價」的 全 鏈 條 研 發 平 台 ， 研 發 實 力 已 躍 居 國 內 第 一 梯 隊 。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 廣東東陽光藥業股份有限公司 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06887 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 112,712,832 | RMB | | 1 | RMB | | 112,712,832 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 112,712,832 | RMB | | 1 | RMB | | 112,712,832 | | 2. 股份分類 ...

Core Viewpoint - Zhang Yushuang, at 38 years old, officially takes over as the sole actual controller of Dongyangguang Group, a private enterprise with total assets exceeding 80 billion yuan, marking a significant transition in leadership and strategy for the company [2][3][5]. Group 1: Leadership Transition - On December 29, 2025, an announcement was made that Guo Meilan transferred all her indirectly held shares in Dongyangguang to Zhang Yushuang, making him the sole actual controller of the company [2][3]. - Prior to the transfer, Zhang Yushuang and Guo Meilan held significant stakes in subsidiaries that controlled 38.70% of Dongyangguang's shares [4]. - This transfer signifies a complete handover of the family business to Zhang Yushuang, as Guo Meilan steps back due to age [7]. Group 2: Company Background - Dongyangguang Group was founded in 1997 by Zhang Zhongneng and Guo Meilan, starting with aluminum foil processing and has since grown into a top 500 private enterprise in China with assets over 80 billion yuan [2][9]. - The company has diversified into three main sectors: electronic new materials, biomedicine, and health care, with two listed companies under its umbrella [2][10]. Group 3: Zhang Yushuang's Experience and Strategy - Zhang Yushuang has 15 years of experience within the company, having started in the research department and gradually moving up to leadership roles [5][6]. - Since taking over, he has initiated a "second entrepreneurship" phase, focusing on transforming the company from traditional manufacturing to intelligent manufacturing, including a significant investment of 28 billion yuan into the IDC sector and advancements in AI and robotics [2][13][16]. - Zhang aims to achieve a target of 50% of products exported, 50% of technology being original, and 50% of revenue coming from high-margin new products by 2030, with a planned R&D investment of 6 billion yuan over the next three years [14][15]. Group 4: Financial Performance and Market Position - As of the end of 2025, the combined market value of Dongyangguang and Dongyangguang Pharmaceutical is approximately 90.6 billion yuan [5]. - The company has shown significant financial improvement, with a net profit of 375 million yuan in 2024, a 227.41% increase year-on-year, and a record net profit of 906 million yuan in the first three quarters of 2025 [16].

Core Viewpoint - Zhang Yushuang, the 38-year-old second-generation leader, officially takes control of Dongyangguang Group, marking a significant transition in the company's leadership and strategy towards innovation and technology-driven growth [2][4][10]. Group 1: Leadership Transition - On December 29, 2025, Dongyangguang announced that Guo Meilan transferred all her indirect shares to Zhang Yushuang, making him the sole actual controller of the company [2][5]. - Zhang Yushuang has been involved in the company for 15 years, starting from a research position and gradually moving up to leadership roles after the passing of his father, Zhang Zhongneng, in November 2020 [8][9]. - The transfer of control signifies the completion of a family succession plan, with Guo Meilan stepping back due to age [9][10]. Group 2: Company Overview - Dongyangguang Group, founded in 1997, has grown into a top 500 private enterprise in China with total assets exceeding 800 billion yuan [2][11]. - The company operates in three main sectors: electronic new materials, biomedicine, and health and wellness, with significant market shares in each area [11][12]. - As of the end of 2025, the combined market value of Dongyangguang and its Hong Kong-listed subsidiary, Dongyangguang Pharmaceutical, is approximately 906 billion yuan [7]. Group 3: Strategic Initiatives - Zhang Yushuang is leading a strategic transformation towards high-value sectors, including the IDC field, AI, and robotics, with a notable investment of 280 billion yuan in the IDC sector [3][18]. - The company aims to enhance its R&D capabilities, planning to invest 60 billion yuan over the next three years to support innovation in new energy materials and biomedicine [16][19]. - Zhang Yushuang has set ambitious goals for the new energy materials sector, targeting 50% of products for export, 50% of technology to be original, and 50% of revenue from high-margin new products by 2030 [16]. Group 4: Financial Performance - In 2024, Dongyangguang achieved a net profit of 3.75 billion yuan, a year-on-year increase of 227.41%, and in the first three quarters of 2025, the net profit reached 9.06 billion yuan, setting a historical record [18]. - The company's R&D expenditures have shown significant growth, with increases of 19.81% and 33.97% in 2024 and the first three quarters of 2025, respectively [18].

Core Insights - The annual operation report meeting of the CICC SAIC Emerging Industries Fund for 2025 was successfully held in Xi'an, focusing on future industries and transformation upgrades [1][13] - The fund has a subscribed scale of 5 billion yuan and has shown stable and healthy operations in 2025, with excellent business performance [3][15] - The fund's investment portfolio covers advanced manufacturing and strategic emerging industries, including sectors like semiconductors, robotics, new energy, artificial intelligence, commercial aerospace, and quantum technology [3][15] Fund Performance - Three star portfolio companies, Zhengli New Energy (03677.HK), Dongyangguang Pharmaceutical (06887.HK), and Muxi Co., Ltd. (688802.SH), successfully went public in 2025 [3][15] - Several portfolio companies have applied for IPOs on A-shares or Hong Kong stocks, including MiniMax, Magnesium Technology, Shenghe Jingwei, and Lingong Heavy Machinery [3][15] - An additional five portfolio companies are expected to apply for IPOs in the first half of 2026 [3][15] Industry Trends - The CICC Capital's representative highlighted key emerging industries and international development trends, including aerospace, quantum technology, nuclear fusion energy, and embodied intelligence [3][15] - The analysis of artificial intelligence development indicated that China's AI industry has formed a systematic and phased development path, with advantages in large model open-source ecosystems and application scenarios [5][17] - The commercial aerospace sector has seen validated business feasibility with the growth of SpaceX, while the low-altitude economy is still in the introduction phase but has clear policy support [7][19] Investment Strategy - The investment strategy emphasizes long-term growth potential in future industries, despite facing uncertainties, compared to mature industries where new entrants face significant challenges [11][23] - The CICC Capital and partners will continue to strengthen collaboration and systematically advance investments in cutting-edge technology fields to support industrial upgrades and development [11][23] - The meeting participants agreed that deepening industry engagement, forward-looking layouts, and open collaboration are essential to navigate changes and embrace a new chapter in Chinese innovation and manufacturing [12][24]

格隆汇1月2日丨东阳光药(06887.HK)公告，1月2日耗资219.2万港元回购4.9万股。 ...